CGRP vs Chonluten

Binds CLR/RAMP1 receptor complex. Causes vasodilation via cAMP/PKA/nitric oxide pathway. Modulates nociceptive signaling in the trigeminal system. Promotes bone healing and has anti-inflammatory effects in peripheral tissues.

CGRP (calcitonin gene-related peptide) is a 37-amino-acid endogenous neuropeptide produced by alternative splicing of the calcitonin gene, expressed predominantly in sensory neurons of the trigeminal system and peripheral vasculature, where it functions as a potent vasodilator and pain neuromodulator central to migraine pathophysiology. CGRP activates its receptor complex (CLR/RAMP1) to mediate vasodilation and nociceptive signal amplification; during migraine attacks, trigeminal activation releases CGRP at elevated plasma concentrations, and blockade of this pathway has been established as the primary validated pharmacological target for modern preventive migraine therapy. Phase 3 randomized controlled trials published in the New England Journal of Medicine and the Lancet — including the STRIVE trial (Goadsby et al. 2017) and a Phase 3b study in treatment-refractory patients — demonstrated that anti-CGRP monoclonal antibodies significantly reduced monthly migraine days versus placebo, validating the pathway and supporting FDA approval of erenumab, fremanezumab, and galcanezumab. CGRP itself is an endogenous neuropeptide and is not a therapeutic agent that is compounded or administered by providers; the FDA-approved interventions are monoclonal antibody and small-molecule receptor antagonists available by prescription, and exogenous CGRP peptide is exclusively a research tool compound used in vasodilatory and pain signaling pharmacology studies.

Tripeptide bioregulator targeting bronchial epithelial cells; normalizes gene expression in bronchial tissue; promotes epithelial regeneration

Chonluten is a synthetic tripeptide (Glu-Asp-Gly, EDG) classified as a Khavinson-class bioregulator peptide targeted at bronchial and lung epithelial tissue, investigated for cytoprotective and anti-aging properties in the respiratory epithelium through proposed gene expression regulatory mechanisms. Like other short Khavinson bioregulator peptides, chonluten is proposed to reach target bronchial cells via proton-coupled oligopeptide transporter (POT) and large amino acid transporter (LAT) uptake mechanisms, and to modulate transcriptional activity in aging or injured lung tissue. Published research on Khavinson-class ultrashort peptides has characterized intracellular transport mechanisms via POT and LAT carriers and demonstrated gene expression regulation by short peptides across multiple tissue types, providing the mechanistic framework within which chonluten's bronchial effects are proposed. Chonluten has no FDA approval or regulatory approval in any major jurisdiction outside Russia; evidence derives from Khavinson-series preclinical and class-level studies with no independent clinical trials published in Western-indexed journals. Chonluten vs cerluten: lung vs bronchial specificity Chonluten is a Khavinson-class short bioregulator peptide proposed to target lung parenchymal tissue rather than the bronchial epithelium (cerluten's proposed target). In the Khavinson organ-specific bioregulator model, different tripeptide or tetrapeptide sequences are proposed to reach distinct tissue types via amino acid transporters and modulate gene expression selectively in those tissues. Chonluten's research applications focus on age-related pulmonary function decline, oxidative stress in lung tissue, and support of alveolar cell function — complementary to but distinct from bronchial applications. Research context for chonluten, like other Khavinson class peptides, comes primarily from the Khavinson Institute (St. Petersburg) preclinical aging models and observational clinical data from Eastern European medical settings; independent large-scale RCT evidence is absent. Standard Khavinson protocol cycles apply: oral capsule, 10–20 day cycles, rest intervals. Chonluten is available from specialty Eastern European suppliers and Russian pharmacy channels; it is not an approved pharmaceutical in Western regulatory jurisdictions. It is sometimes stacked with cerluten in protocols targeting comprehensive respiratory tissue support, though no clinical evidence for this combination exists.